GEN Exclusives

More »

GEN News Highlights

More »
Oct 22, 2012

Hikma Nabs Prostate Cancer Drug for MENA Region

  • Hikma Pharmaceuticals negotiated rights to register, market, and distribute GP Pharm’s lead androgen deprivation therapy Lutrate® 1 month (leuprolide acetate 3.75 mg) in 23 countries in the Middle East and North Africa (MENA) region. The new deal will also position Hikma as GP Pharm’s preferred partner for its pipeline of oncology products in the MENA region.

    The prostate cancer drug Lutrate is currently approved in the EU, and regulatory filings in the U.S. and other countries are projected for the near future. GP Pharm is in addition developing 3-month and 6-month depot formulations.

    With expertise in drug delivery systems including microspheres and liposomes, Spanish biopharma GP Pharm is focused on the development, manufacture, and commercialization of injectable drugs for urology and oncology indications. Lutrate 1 month is the first drug developed by GP Pharm right through from research through to market launch and commercialization, making the firm one of the only Spanish biotechs to have achieved its own product launch.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Climate Change and Disease

Are the incursions of dengue fever and West Nile virus into North America just the tip of the iceberg of insect-borne diseases that are migrating due to a warming planet?